TIDMPRTC

PureTech Health PLC

09 November 2017

9 November 2017

PureTech Health plc

PureTech Health to Present at Jefferies 2017 Healthcare Conference in London

PureTech Health plc (LSE: PRTC), an advanced, clinical-stage biopharmaceutical company, today announced that Eric Elenko, PhD, Chief of Research and Strategy at PureTech Health, will present at the Jefferies 2017 Global Healthcare Conference in London on Thursday, 16 November, at 8.00AM GMT. A webcast of the presentation will be available at http://puretechhealth.com/investors under the Reports and Presentations tab.

About PureTech Health

PureTech Health (PureTech Health plc, PRTC.L) is an advanced, clinical-stage biopharmaceutical company developing novel medicines targeting serious diseases that result from dysfunctions in the nervous, immune, and gastrointestinal systems (brain-immune-gut or the "BIG" axis), which together represent the adaptive human systems. PureTech Health is at the forefront of understanding and addressing the biological processes and crosstalk associated with the BIG axis. By harnessing this emerging field of human biology, the Company is pioneering new categories of medicine with the potential to have great impact on people with serious diseases. PureTech Health is advancing a rich pipeline of innovative therapies that includes two pivotal stage programmes, multiple human proof-of-concept studies and a number of early clinical and pre-clinical programmes. PureTech's rich research and development pipeline has been advanced in collaboration with some of the world's leading scientific experts, who along with PureTech's team of biopharma pioneers, entrepreneurs and seasoned Board, identify, invent, and clinically de-risk new medicines. With this experienced team pursuing cutting edge science, PureTech Health is building the biopharma company of the future focused on improving and extending the lives of people with serious disease. For more information, visit www.puretechhealth.com or connect with us on Twitter @puretechh.

Forward Looking Statement

This press release contains statements that are or may be forward-looking statements, including statements that relate to the company's future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks and uncertainties described in the risk factors included in the regulatory filings for PureTech Health plc. These forward-looking statements are based on assumptions regarding the present and future business strategies of the company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, neither the company nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:

 
   PureTech Health           FTI Consulting 
   Allison Mead Talbot       Ben Atwell, Rob 
    +1 617 651 3156           Winder 
    amt@puretechhealth.com    +44 (0) 20 3727 
                              1000

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAOKFDDBBDBNDK

(END) Dow Jones Newswires

November 09, 2017 02:02 ET (07:02 GMT)

Puretech Health (LSE:PRTC)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Puretech Health Charts.
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Puretech Health Charts.